The struggling genetic-testing 23andMe is looking for a buyer for the virtual-care business it acquired in 2021, Business ...
Shares in 23andMe are currently trading at around $3.40, giving it a valuation of just under $82 million. The company went ...
Genetic testing pioneer 23andMe is looking at strategic alternatives, including a possible sale, it said Tuesday, months ...
Me (ME) forms special board committee to explore strategic alternatives, including sale, restructuring, or business ...
The struggling health company bought the virtual-care startup Lemonaid in 2021 for $400 million. 23andMe's stock plummeted after a 2023 data breach exposed millions of customer accounts.
Investing.com -- Genetic testing firm 23andMe is reportedly considering the sale of its telehealth division, Lemonaid Health, according to Business Insider. The company, which has faced financial ...